by American Society of Hematology New data suggest that people who have a parent, sibling, or child with blood cancer have a higher likelihood of being diagnosed with the disease. The study published online today in Blood offers the first evidence that such familial risks exist across the spectrum of hematologic malignancies. Age of diagnosis, whether the...
Tag: <span>Blood cancer</span>
Post
New cancer therapy target found in mitochondria for potential treatment of blood cancers
by University of Texas M. D. Anderson Cancer Center A study at The University of Texas MD Anderson Cancer Center identified a new therapeutic target in cancer cells and explains how new anti-cancer drugs called imipridones work by inducing cancer cell death in blood cancers, such as acute myeloid leukemia (AML) and mantle cell lymphoma. The study revealed a target in mitochondria, called caseinolytic protease P (ClpP), which, upon activation, breaks down proteins within mitochondria, a process...
Post
Gene therapy may help fight tough-to-treat blood cancer
by Amy Norton, Healthday Reporter (HealthDay)—A gene therapy that tweaks the immune system might offer hope to people with blood cancer that has resisted standard treatments, a new preliminary trial suggests. The cancer, called multiple myeloma, arises in certain white blood cells. It is currently incurable, but there are treatments that can help people live with the disease for years. However, most people eventually progress, and some fail to respond to the available therapies...
Post
Blood cancer’s Achilles’ heel opens door for new treatments
UNIVERSITY OF EDINBURGH New findings about a fatal form of blood cancer could aid the development of new drugs with significantly less harmful side effects than existing chemotherapy. The discovery could lead to novel treatments that efficiently eliminate blood cancer cells in acute myeloid leukaemia (AML), without harming healthy blood cells. Researchers have discovered how a protein in the body plays a key role in AML...
Post
New therapy for aggressive blood cancer discovered
Acute myeloid leukemia (AML) is the most common form of acute leukemia. It is characterized by an increase of malignant myeloid progenitor cells at the expense of mature blood cells. Only twenty-five percent of all AML patients survive five years beyond the initial diagnosis. Therefore there is an urgent need to deepen the knowledge about...
Post
Stem cells show promise as drug delivery tool for childhood brain cancer
The latest in a series of laboratory breakthroughs could lead to a more effective way to treat the most common brain cancer in children. Scientists from the University of North Carolina Lineberger Comprehensive Cancer Center, UNC Eshelman School of Pharmacy, and the UNC School of Medicine reported results from early studies that demonstrate how cancer-hunting...
Post
New drugs are improving survival times for patients with aggressive type of blood cancer, study finds
Survival times for a highly aggressive type of blood cancer have nearly doubled over the last decade due to the introduction of new targeted drugs, a Yorkshire study has shown. The University of York and NHS clinicians followed the treatment of 335 people with mantle cell lymphoma (MCL) in hospitals across Yorkshire and Humberside between 2004 and 2015. Survival times...
Post
A new Achilles’ heel of blood cancer
New potential target identified to fight acute myeloid leukemia CEMM RESEARCH CENTER FOR MOLECULAR MEDICINE OF THE AUSTRIAN ACADEMY OF SCIENCES (Vienna, May 18, 2018) AML is not a single disease. It is a group of leukemias that develop in the bone marrow from progenitors of specialized blood cells, the so-called myeloid cells. Rapidly growing and dividing,...
Post
New cancer drug shows promise in helping patients with blood cancer
An immunology discovery from the laboratories at the University of Southampton has now been shown to improve the outcomes of a common type of blood cancer in patients. Follicular lymphoma is a type of non-Hodgkin lymphoma and develops when the body makes abnormal white blood cells that fight infection, called B-lymphocytes. It can be slow-growing...
Post
US regulators approve 2nd gene therapy for blood cancer
In this May 2016 file photo provided by Kite Pharma, cell therapy specialists at the company’s manufacturing facility in El Segundo, Calif., prepare blood cells from a patient to be engineered in the lab to fight cancer. On Wednesday, Oct. …more U.S. regulators on Wednesday approved a second gene therapy for a blood cancer, a...